Stephanie L Constant1, Robert J Freishtat2,3, Erik J Stemmy1, Angela S Benton2, Jennifer Lerner2, Sarah Alcala1. 1. Department of Microbiology, Immunology, and Tropical Medicine, The George Washington University Medical Center, Washington D.C., USA. 2. Center for Genetic Medicine Research, Children's National Medical Center, Washington D.C., USA. 3. Departments of Pediatrics, Emergency Medicine, and Integrative Systems Biology, The George Washington University Medical Center, Washington D.C., USA.
Abstract
OBJECTIVE: Leukocyte persistence during chronic (quiescent) phases of asthma is a major hallmark of the disease. The mechanisms regulating these persistent leukocyte populations are not clearly understood. An alternative family of chemoattracting proteins, cyclophilins (Cyps), has recently been shown to contribute to leukocyte recruitment in animal models of allergic asthma. The goals of this study were to determine whether Cyps are present in asthma patients during the chronic phase of the disease and to investigate whether levels of Cyps associate with clinical parameters of disease severity. METHODS: Nasal wash samples from an urban cohort of 137 patients of age 6-20 years with physician-diagnosed asthma were examined for the presence of cyclophilin A (CypA), cyclophilin B (CypB), as well as several other classical chemokines. Linear, logistic, or ordinal regressions were performed to identify associations between Cyps, chemokines, and clinical parameters of asthma. The asthma cohort was further divided into previously established phenotypic clusters (cluster 1: n = 55; cluster 2: n = 31; and cluster 3: n = 51) and examined for associations. RESULTS: Levels of CypB in the asthma group were highly elevated compared to nonasthmatic controls, while a slight increase in Monocyte Chemotactic Protein-1 (MCP-1) was also observed. CypA and MCP-1 were associated with levels of eosinophil cationic protein (ECP; a marker of eosinophil activation). Cluster-specific associations were found for CypA and CypB and clinical asthma parameters [e.g. forced expiratory volume in 1 second (FEV(1)) and ECP]. CONCLUSIONS: Cyps are present in nasal wash samples of asthma patients and may be a novel biomarker for clinical parameters of asthma severity.
OBJECTIVE: Leukocyte persistence during chronic (quiescent) phases of asthma is a major hallmark of the disease. The mechanisms regulating these persistent leukocyte populations are not clearly understood. An alternative family of chemoattracting proteins, cyclophilins (Cyps), has recently been shown to contribute to leukocyte recruitment in animal models of allergic asthma. The goals of this study were to determine whether Cyps are present in asthmapatients during the chronic phase of the disease and to investigate whether levels of Cyps associate with clinical parameters of disease severity. METHODS: Nasal wash samples from an urban cohort of 137 patients of age 6-20 years with physician-diagnosed asthma were examined for the presence of cyclophilin A (CypA), cyclophilin B (CypB), as well as several other classical chemokines. Linear, logistic, or ordinal regressions were performed to identify associations between Cyps, chemokines, and clinical parameters of asthma. The asthma cohort was further divided into previously established phenotypic clusters (cluster 1: n = 55; cluster 2: n = 31; and cluster 3: n = 51) and examined for associations. RESULTS: Levels of CypB in the asthma group were highly elevated compared to nonasthmatic controls, while a slight increase in Monocyte Chemotactic Protein-1 (MCP-1) was also observed. CypA and MCP-1 were associated with levels of eosinophil cationic protein (ECP; a marker of eosinophil activation). Cluster-specific associations were found for CypA and CypB and clinical asthma parameters [e.g. forced expiratory volume in 1 second (FEV(1)) and ECP]. CONCLUSIONS: Cyps are present in nasal wash samples of asthmapatients and may be a novel biomarker for clinical parameters of asthma severity.
Authors: Erik J Stemmy; Molly A Balsley; Rosalyn A Jurjus; Jesse M Damsker; Michael I Bukrinsky; Stephanie L Constant Journal: Am J Respir Cell Mol Biol Date: 2011-04-14 Impact factor: 6.914
Authors: Molly A Balsley; Miroslav Malesevic; Erik J Stemmy; Jason Gigley; Rosalyn A Jurjus; Dallen Herzog; Michael I Bukrinsky; Gunter Fischer; Stephanie L Constant Journal: J Immunol Date: 2010-11-05 Impact factor: 5.422
Authors: Robert J Freishtat; Sabah F Iqbal; Dinesh K Pillai; Catherine J Klein; Leticia M Ryan; Angela S Benton; Stephen J Teach Journal: J Pediatr Date: 2010-03-16 Impact factor: 4.406
Authors: Angela S Benton; Nikila Kumar; Jennifer Lerner; Andrew A Wiles; Matthew Foerster; Stephen J Teach; Robert J Freishtat Journal: J Investig Med Date: 2010-12 Impact factor: 2.895
Authors: Alan M Watson; Wai-Man Ngor; Heather Gordish-Dressman; Robert J Freishtat; Mary C Rose Journal: J Investig Med Date: 2009-12 Impact factor: 2.895
Authors: Lisa Maltz; Ethan L Matz; Heather Gordish-Dressman; Dinesh K Pillai; Stephen J Teach; Carlos A Camargo; Monica J Hubal; Simran Behniwal; Guy D Prosper; Nicole Certner; Raman Marwah; Douglas M Mansell; Fisayo Nwachukwu; Risa Lazaroff; Yodit Tsegaye; Robert J Freishtat Journal: Pediatr Pulmonol Date: 2016-01-15
Authors: Eduardo Castro-Nallar; Ying Shen; Robert J Freishtat; Marcos Pérez-Losada; Solaiappan Manimaran; Gang Liu; W Evan Johnson; Keith A Crandall Journal: BMC Med Genomics Date: 2015-08-16 Impact factor: 3.063